Suppr超能文献

系统泛癌症分析鉴定 TREM2 为一种免疫和预后生物标志物。

Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.

机构信息

Department of Integrated Traditional Chinese & Western Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.

Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China.

出版信息

Front Immunol. 2021 Feb 17;12:646523. doi: 10.3389/fimmu.2021.646523. eCollection 2021.

Abstract

Triggering receptor expressed on myeloid cells-2 (TREM2) is a transmembrane receptor of the immunoglobulin superfamily and a crucial signaling hub for multiple pathological pathways that mediate immunity. Although increasing evidence supports a vital role for TREM2 in tumorigenesis of some cancers, no systematic pan-cancer analysis of TREM2 is available. Thus, we aimed to explore the prognostic value, and investigate the potential immunological functions, of TREM2 across 33 cancer types. Based on datasets from The Cancer Genome Atlas, and the Cancer Cell Line Encyclopedia, Genotype Tissue-Expression, cBioPortal, and Human Protein Atlas, we employed an array of bioinformatics methods to explore the potential oncogenic roles of TREM2, including analyzing the relationship between TREM2 and prognosis, tumor mutational burden (TMB), microsatellite instability (MSI), DNA methylation, and immune cell infiltration of different tumors. The results show that TREM2 is highly expressed in most cancers, but present at low levels in lung cancer. Further, TREM2 is positively or negatively associated with prognosis in different cancers. Additionally, TREM2 expression was associated with TMB and MSI in 12 cancer types, while in 20 types of cancer, there was a correlation between TREM2 expression and DNA methylation. Six tumors, including breast invasive carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, kidney renal clear cell carcinoma, lung squamous cell carcinoma, skin cutaneous melanoma, and stomach adenocarcinoma, were screened out for further study, which demonstrated that TREM2 gene expression was negatively correlated with infiltration levels of most immune cells, but positively correlated with infiltration levels of M1 and M2 macrophages. Moreover, correlation with TREM2 expression differed according to T cell subtype. Our study reveals that TREM2 can function as a prognostic marker in various malignant tumors because of its role in tumorigenesis and tumor immunity.

摘要

髓系细胞触发受体 2(TREM2)是免疫球蛋白超家族的跨膜受体,是介导免疫的多种病理途径的关键信号枢纽。尽管越来越多的证据支持 TREM2 在某些癌症的肿瘤发生中起着至关重要的作用,但目前尚无针对 TREM2 的泛癌症系统分析。因此,我们旨在探讨 TREM2 在 33 种癌症类型中的预后价值,并研究其潜在的免疫功能。基于来自癌症基因组图谱(TCGA)、癌症细胞系百科全书(CCLE)、基因型组织表达(GTEx)、cBioPortal 和人类蛋白质图谱(HPA)的数据集,我们采用了一系列生物信息学方法来探讨 TREM2 的潜在致癌作用,包括分析 TREM2 与预后、肿瘤突变负担(TMB)、微卫星不稳定性(MSI)、DNA 甲基化和不同肿瘤的免疫细胞浸润之间的关系。结果表明,TREM2 在大多数癌症中高表达,但在肺癌中低表达。此外,TREM2 在不同癌症中的表达与预后呈正相关或负相关。此外,TREM2 的表达与 12 种癌症类型的 TMB 和 MSI 相关,而在 20 种癌症类型中,TREM2 的表达与 DNA 甲基化相关。筛选出包括乳腺癌浸润性癌、宫颈鳞状细胞癌和宫颈内膜腺癌、肾透明细胞癌、肺鳞状细胞癌、皮肤黑色素瘤和胃腺癌在内的 6 种肿瘤进行进一步研究,结果表明 TREM2 基因表达与大多数免疫细胞浸润水平呈负相关,但与 M1 和 M2 巨噬细胞浸润水平呈正相关。此外,TREM2 表达与 T 细胞亚群的相关性因肿瘤而异。我们的研究表明,TREM2 可以作为各种恶性肿瘤的预后标志物,因为它在肿瘤发生和肿瘤免疫中发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e0a/7925850/8b3a962b4082/fimmu-12-646523-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验